Výsledky vyhledávání - "György, Horvath"

mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy

Autor: Peter Söderkvist, György Horvath, Henrik Gréen, Per Rosenberg, Carsten Peterson

Publikováno v: Clinical Cancer Research. 12:854-859

Purpose: P-glycoprotein, encoded by the mdr-1 gene, confers multidrug resistance to a variety of antineoplastic agents, e.g., paclitaxel. Recently, different polymorphisms in the mdr-1 gene have been identified and their consequences for the function

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0f44f4c2574aa786e180b21461c1da3
https://doi.org/10.1158/1078-0432.ccr-05-0950

Zobrazit plný text záznamu

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

Autor: Marianne Graflund, György Horvath, Bengt Sorbe, Lisa Nygren

Publikováno v: Oncology Letters

The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4adac1c6109f49b89545ec880de18c3d
https://doi.org/10.3892/ol.2013.1146

Zobrazit plný text záznamu

External Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma: A Prospective, Randomized Study—Quality-of-Life Analysis

Autor: Karin Boman, Håkan Andersson, György Horvath, Caroline Lundgren, Bengt Sorbe, Birgitta Pettersson

Publikováno v: International Journal of Gynecologic Cancer. 22:1281-1288

BackgroundA combination of vaginal brachytherapy and external beam radiotherapy was compared with brachytherapy alone in medium-risk endometrial carcinomas. Quality-of-life analysis is an important part of a randomized study to find out the optimal a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ab55fe5baf6185c7117d39d75a8c895
https://doi.org/10.1097/igc.0b013e3182643ba0

Zobrazit plný text záznamu

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

Autor: Marianne Graflund, Bengt Sorbe, Margareta Lood, Karin Boman, Marie Swahn, Henric Malmström, Rene Bangshoj, György Horvath

Publikováno v: International Journal of Gynecologic Cancer. 22:47-53

ObjectivesThe purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carbo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b33d9f0d49cb49ebf4b366348d720af
https://doi.org/10.1097/igc.0b013e318234fa3a

Zobrazit plný text záznamu

Identification of a Gene Expression Signature for Survival Prediction in Type I Endometrial Carcinoma

Autor: Lovisa Österberg, Ulla Delle, Björn Olsson, Saskia Eklind, Kristina Levan, György Horvath, Karolina Partheen

Publikováno v: Gene Expression. 14:361-370

Endometrial cancer is the most common malignancy of the female reproductive tract. In many cases the prognosis is favorable, but 22% of affected women die from the disease. We aimed to study potential differences in gene expression between endometrio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::609e8ef2109a10948a5b58c3f3c31df5
https://doi.org/10.3727/105221610x12735213181242

Zobrazit plný text záznamu

High-Resolution Genomic Profiling of Carboplatin Resistance in Early-Stage Epithelial Ovarian Carcinoma

Autor: Lovisa Österberg, Johan Staaf, Karolina Partheen, Karin Sundfeldt, Kristina Levan, György Horvath

Publikováno v: Cytogenetic and Genome Research. 125:8-18

Chemotherapy resistance remains a major obstacle to successful treatment of ovarian cancer patients. Therefore, increased knowledge of underlying mechanisms and identification of predictive factors are of great importance. Standard treatment for ovar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8db101a85ccb4812a4b818cd4b08ce
https://doi.org/10.1159/000218744

Zobrazit plný text záznamu

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

Autor: Karin Sundfeldt, Karolina Partheen, Kristina Levan, Ghita Fallenius, György Horvath, Ingela Claesson, Lovisa Österberg

Publikováno v: International Journal of Cancer. 123:2130-2137

The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd366cc68c537d2c70b84ad25a1b369
https://doi.org/10.1002/ijc.23758

Zobrazit plný text záznamu

ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel

Autor: Peter Söderkvist, Carsten Peterson, Per Rosenberg, Henrik Gréen, György Horvath

Publikováno v: Journal of Pharmaceutical Sciences. 97:2045-2048

P-glycoprotein (P-gp), encoded by the ABCB1 gene, confers multi-drug resistance to a variety of antineoplastic agents, for example, paclitaxel. Recently, the G1199T/A polymorphism in the ABCB1 gene was shown to be important for the function of P-gp a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f386541fbe911a85d5618d3e722f0376
https://doi.org/10.1002/jps.21169

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání